The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Francis Medical in Maple Grove has raised about $160 million — and wants to roughly double this — as it plans for an initial ...

Metastatic castration-resistant prostate cancer is a complicated disease ... doctors must consider several factors, including your symptoms, personal preferences, and other health conditions ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has spread before treatment, detecting recurrence in patients with rising ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the ...

While one has to be careful even for the slightest of symptoms at any age, there is something that one doctor wishes to make clear to those who think prostate cancer is just for men under 50 years of ...

Micro-ultrasound–guided biopsies were found for the first time to be “noninferior” to MRI-guided procedures, according to new research presented at the 2025 annual congress of the European ...

If detected at an early stage, prostate cancer is manageable and need not cause fear. However, in most cases, early symptoms go unnoticed. Therefore, it is crucial to be aware of the signs of this ...